TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Conditions
- Advanced Colorectal Carcinoma
- Metastatic Colon Adenocarcinoma
- Metastatic Rectal Adenocarcinoma
- Recurrent Colon Adenocarcinoma
- Recurrent Colorectal Adenocarcinoma
- Recurrent Rectal Adenocarcinoma
- Stage III Colon Cancer AJCC v8
- Stage III Colorectal Cancer AJCC v8
- Stage III Rectal Cancer AJCC v8
- Stage IIIA Colon Cancer AJCC v8
- Stage IIIA Colorectal Cancer AJCC v8
- Stage IIIB Colorectal Cancer AJCC v8
- Stage IIIB Rectal Cancer AJCC v8
- Stage IIIC Colon Cancer AJCC v8
- Stage IIIC Colorectal Cancer AJCC v8
- Stage IV Colon Cancer AJCC v8
- Stage IVA Colorectal Cancer AJCC v8
- Stage IVA Rectal Cancer AJCC v8
- Stage IVB Colon Cancer AJCC v8
- Stage IVB Colorectal Cancer AJCC v8
- Stage IVB Rectal Cancer AJCC v8
- Stage IVC Colon Cancer AJCC v8
- Stage IVC Colorectal Cancer AJCC v8
- Stage IVC Rectal Cancer AJCC v8
- Unresectable Colon Adenocarcinoma
- Unresectable Colorectal Carcinoma
- Unresectable Rectal Adenocarcinoma
Interventions
- DRUG: Irinotecan
- BIOLOGICAL: Bevacizumab
- DRUG: Trifluridine and Tipiracil Hydrochloride
Sponsor
Roswell Park Cancer Institute
Collaborators